Paper41003134
Metabolic Signature of FLT3-Mutated AML: Clinical and Therapeutic Implications.
Banella C and 5 others. J Pers Med, 2025. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Metabolic Signature of FLT3-Mutated AML: Clinical and Therapeutic Implications. Papers, record 41003134. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41003134
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| DR3392 | Italian Association for Cancer Research | PubMed | ||
| M4C2I1.3 | Ministero dell'università e della ricerca | PubMed |
Source PubMed
References190
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32786187 | Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32786187 | PubMed |
| 2 | 23333149 | BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. | Cell Stem Cell | 2013 | https://conductscience.org/library/papers/23333149 | PubMed |
| 3 | 28283480 | Leveraging increased cytoplasmic nucleoside kinase activity to target mtDNA and oxidative phosphorylation in AML. | Blood | 2017 | https://conductscience.org/library/papers/28283480 | PubMed |
| 5 | 26219591 | An MTCH2 pathway repressing mitochondria metabolism regulates haematopoietic stem cell fate. | Nat Commun | 2015 | https://conductscience.org/library/papers/26219591 | PubMed |
| 6 | 25547679 | Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations. | Clin Cancer Res | 2015 | https://conductscience.org/library/papers/25547679 | PubMed |
| 7 | 36831684 | Repurposing Atovaquone as a Therapeutic against Acute Myeloid Leukemia (AML): Combination with Conventional Chemotherapy Is Feasible and Well Tolerated. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/36831684 | PubMed |
| 8 | 27540013 | Targeting FLT3-ITD signaling mediates ceramide-dependent mitophagy and attenuates drug resistance in AML. | Blood | 2016 | https://conductscience.org/library/papers/27540013 | PubMed |
| 9 | 29326164 | The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5). | J Biol Chem | 2018 | https://conductscience.org/library/papers/29326164 | PubMed |
| 10 | 39902131 | Mitochondrial abnormalities as a target of intervention in acute myeloid leukemia. | Front Oncol | 2024 | https://conductscience.org/library/papers/39902131 | PubMed |
| 11 | 35797463 | Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. | Blood | 2022 | https://conductscience.org/library/papers/35797463 | PubMed |
| 12 | 35962843 | Invariant NKT cells metabolically adapt to the acute myeloid leukaemia environment. | Cancer Immunol Immunother | 2023 | https://conductscience.org/library/papers/35962843 | PubMed |
| 13 | 38179723 | The Potential Transcriptomic and Metabolomic Mechanisms of ATO and ATRA in Treatment of FLT3-ITD Acute Myeloid Leukemia. | Technol Cancer Res Treat | 2024 | https://conductscience.org/library/papers/38179723 | PubMed |
| 14 | 37349598 | MCL1 regulates AML cells metabolism via direct interaction with HK2. Metabolic signature at onset predicts overall survival in AMLs' patients. | Leukemia | 2023 | https://conductscience.org/library/papers/37349598 | PubMed |
| 15 | 31819187 | New aspects of amino acid metabolism in cancer. | Br J Cancer | 2020 | https://conductscience.org/library/papers/31819187 | PubMed |
| 16 | 29472349 | Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group. | Haematologica | 2018 | https://conductscience.org/library/papers/29472349 | PubMed |
| 17 | 18287083 | Nrf2 mediates cancer protection but not prolongevity induced by caloric restriction. | Proc Natl Acad Sci U S A | 2008 | https://conductscience.org/library/papers/18287083 | PubMed |
| 18 | 16998484 | Targeting of CD44 eradicates human acute myeloid leukemic stem cells. | Nat Med | 2006 | https://conductscience.org/library/papers/16998484 | PubMed |
| 19 | 25215489 | Cell-state-specific metabolic dependency in hematopoiesis and leukemogenesis. | Cell | 2014 | https://conductscience.org/library/papers/25215489 | PubMed |
| 20 | 30975911 | FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways. | Haematologica | 2019 | https://conductscience.org/library/papers/30975911 | PubMed |
| 21 | 24014241 | Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. | Blood | 2013 | https://conductscience.org/library/papers/24014241 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42797430 | Exploiting Metabolic Vulnerabilities in Acute Myeloid Leukemia: Rationale and Evidence for Combining Metabolic Modulators with Conventional Chemotherapy. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42797430 | PubMed |
| 41463291 | Mitochondrial Dysfunction in Apoptosis-Resistant Acute Myeloid Leukemia Cells During a Sterile Inflammatory Response. | Biomolecules | 2025 | https://conductscience.org/library/papers/41463291 | PubMed |
Genes76
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41003134
GET https://conductscience.org/api/papers/v1/41003134/references?page=2